Table 1

Clinical features of patients with anti-TIF1β autoantibodies.

1

2

3

4


Diagnosis

DM

UCTD

DM

DM

Symmetrical muscle weakness

P

N

P

Y

Muscle biopsy

Y

ND

ND

NA

Elevated muscle enzyme

Y

Y

Y

Y

EMG

myopathic pattern

myopathic pattern

myopathic pattern

NA

Dermatologic features

Y (G)

N

P (S)

Y (G, H, S)

Malignancy

N

Y

N

N

Interstitial lung disease

N

N

N

N

Dysphagia

Y

N

N

N

Raynaud's phenomenon

N

N

N

N

Arthritis

N

Y

N

N

CPK (U/L) initial

/after Tx (lowest)

654

167

341

239

314

2414

Initial Tx

none

PSL 10 mg

PSL 40 mg

PSL 50 mg

HCQ 200 mg

NSAIDs

HCQ 200 mg

MTX 20 mg/w

HCQ 150 mg

Response to Tx

NA

good

good

good

Other autoantibodies

Ro, Su, U1RNP (Sm)

Mi-2, Su

ELISA (RP) TIF1α

-

-

+

-

TIF1β

+

+

-

-

TIF1γ

-

-

-

-

antigen-capture ELISA

TIF1α

-

-

-

-

TIF1β

+

+

weak +

weak +


DM, dermatomyositis; ELISA, enzyme-linked immunosorbent assay; EMG, electromyogram; G, Gottron; H, heliotrope; HCQ, hydroxychloroquine; MTX, methotrexate; N, no; NA, not available; ND, not done; NSAIDs, non-steroid anti-inflammatory drugs; P, possible; PSL, prednisolone; RP, recombinant protein; S, shawl sign; TIF, transcription intermediary factor; Tx, treatment; UCTD, undifferentiated connective tissue disease; Y, yes;

Satoh et al. Arthritis Research & Therapy 2012 14:R79   doi:10.1186/ar3802

Open Data